Clinical trials: Dopamine Receptor Occupancy
Schizophrenia
A Positron-Emission-Tomography (PET) Study to Measure the Blockade of Dopamine Receptors (D2) in Specific Areas of the Brain in Relation to the Plasma Concentrations of Paliperidone Extended Release (ER) and Oral Risperidone in Schizophrenia Patients and Healthy Controls
The primary objective of this study is to compare the effect of two different antipsychotic compounds which are used in the treatment of schizophrenia (paliperidone ER and risperidone) at their target sites in two specific areas…
- Trial name
- NCT00934635
- Testing
- Paliperidone ER, Oral risperidone, PET Scan
- Where
- Germany
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- Janssen-Cilag G.m.b.H
Schizophrenia
Predicting Antipsychotic Discontinuation in Psychosis
The purpose of this study is to determine whether dopamine synthesis capacity by using [18 fluorine(F)]-DOPA PET for patients with schizophrenia in the maintenance phase can predict treatment discontinuation.
- Trial name
- PADP (NCT02884518)
- Testing
- PET, clinical scale
- Where
- South Korea
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Schizophrenia Disorder
A Positron Emission Tomography (PET) Study to Evaluate Dopamine D2 and D3 Receptor Occupancy by SIPI6398
This is an open label study in 2 cohorts of healthy volunteers and 1 cohort of patients with Schizophrenia, designed to evaluate the Dopamine D2 and D3 Receptor Occupancy by SIPI6398 at various doses and timepoints.
- Trial name
- NCT07626034
- Testing
- SIPI6398 Tablets
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Shanghai Zhongze Therapeutics Co., Ltd.
Healthy Volunteers
An Open Label Phase I/II Study of Dopamine Transporter Receptor Occupancy With OROS and Immediate Release Methylphenidate as Measured With C-11 Altropane in Human Subjects
The specific aim of this study is to document the pharmacokinetics of DAT receptor occupancy of OROS and immediate release (IR) MPH using PET scanning with C-11 altropane as the ligand.
- Trial name
- NCT00302367
- Testing
- OROS methylphenidate hydrochloride, immediate release methylphenidate hydrochloride
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Schizophrenia
Receptor Occupancy of LB-102 Using Positron Emission Tomography (PET) in Healthy Volunteers
This is an open label study in 4 cohort of 4 healthy volunteers each designed to evaluate the dopamine receptor occupancy of LB-102 at various doses and timepoints.
- Trial name
- NCT04588129
- Testing
- LB-102
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- LB Pharmaceuticals Inc.
D3 Dopamine Receptor, Cocaine-dependent
Evaluation of D3 Receptor Occupancy Using FLUORTRIOPRIDE ([18F]FTP) PET/CT
Preclinical work suggests that D3 dopamine receptors may be important in the study of the pathophysiology of affective disorders, psychotic disorders and addiction.
- Conditions
- D3 Dopamine Receptor, Cocaine-dependent, Healthy Volunteer
- Trial name
- NCT02815917
- Testing
- [18F]FTP PET/CT
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Healthy Men
D2 Dopamine Receptor Occupancy After Oral Dosing of Lu AF35700 in Healthy Men Using [11C]-PHNO as Tracer Compound
To investigate the relationship between the combined Lu AF35700 and Lu AF36152 plasma concentration and D2 dopamine receptor occupancy up to 172 hours after oral dosing of Lu AF35700
- Trial name
- NCT02093169
- Testing
- Part A: Lu AF35700, Part B: Lu AF35700
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- H. Lundbeck A/S
Schizophrenia
[18 Fluorine(F)]DOPA Determinants and Predictors of Treatment Response in Psychosis
The first purpose of this study is to determine if dopamine synthesis capacity is significantly lower in treatment non-responders from illness onset relative to treatment responders.
- Trial name
- DPTP (NCT02880995)
- Testing
- PET scan, clinical scale, 6 weeks of treatment with amisulpride
- Where
- 2 sites in South Korea
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Drug Binding to DAT Receptors
Study of Dopamine Transporter Receptor Occupancy With Long-acting Dex-methylphenidate
The objectives of this study are to document the pharmacokinetics of the adequacy of DAT receptor occupancy d-MPH formulation in three doses (20 mg, 30 mg, and 40 mg) using PET scanning with C-11 Altropane as the ligand across a…
- Trial name
- NCT00593138
- Testing
- dex-methylphenidate
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Schizophrenia
A Study of Dopamine Type 2 (D2) Receptor Occupancy Following a Single Oral Dose of OROS Paliperidone
The purposes of this study are to estimate the relationship of D2-receptor occupancy to plasma concentration and to assess the safety of OROS paliperidone.
- Trial name
- NCT00796432
- Testing
- OROS paliperidone
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Depression
Positron Emission Tomography (PET) Study With [11C]Raclopride to Determine Central D2 Dopamine Occupancy of SEROQUEL
The aim of this study is to relate pharmacokinetics of two different formulations of quetiapine to PET measured receptor occupancy in the brains of healthy subjects.
- Trial name
- PET (NCT00832221)
- Testing
- SEROQUEL XR (quetiapine), SEROQUEL IR (quetiapine), radioligand [11C]raclopride
- Where
- Sweden
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy Subjects
Study of Safety, Blood Levels and Brain Receptor Occupancy of GSK598809 Using PET Imaging in Health Males.
The purpose of this study is to look at how much of a new drug, GSK598809 binds to specific proteins in the brain and how much stays in the blood over a range of different doses.
- Trial name
- NCT00468806
- Testing
- GSK598809, using [11C]-(+)-PHNO
- Where
- Canada
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Substance Dependence
An Open Label Positron Emission Tomography (PET) Study of GSK618334 in Healthy Male Subjects Using 11C-PHNO as PET Ligand
The purpose of this study is to investigate the relationship between the plasma concentrations of the study drug and the amount of the study drug bound to the D3 receptors of the brain after dosing of a new compound GSK618334.
- Trial name
- NCT00814957
- Testing
- GSK618334
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy Volunteers
A PET Study Examining Pharmacokinetics and Dopamine Transporter Receptor Occupancy Of Two Long-Acting Formulations of Methylphenidate in Adults
The specific aim of this study is to document the pharmacokinetics of dopamine transporter DAT receptor occupancy of OROS MPH and Metadate CD using PET scanning with C-11 Altropane as the ligand.
- Trial name
- NCT00301639
- Testing
- OROS methylphenidate hydrochloride, methylphenidate hydrochloride
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Healthy
Study Examining Repeat Dosing of OROS® Methylphenidate (CONCERTA®) and Immediate Release Methylphenidate in Healthy Adults
There are two specific aims of this study. The first is to document the pharmacokinetics of dopamine transporter (DAT) receptor occupancy of repeated administration of orally administered, therapeutic doses of a short immediate…
- Trial name
- NCT00302393
- Testing
- OROS methylphenidate hydrochloride, methylphenidate hydrochloride
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Healthy Volunteers
Study of Oral ABBV-932 Capsules to Evaluate Dopamine D2 and D3 Receptor Occupancy in Brain in Adult Healthy Volunteers
The main objective of this study is to evaluate the dopamine D2 and D3 receptor occupancy in the brain as measured by PET with radiotracer [11C]-(+)-PHNO up to 14 days of once-daily oral doses of ABBV-932 in healthy subjects.
- Trial name
- Ph1PET UK Stdy (NCT06300580)
- Testing
- ABBV-932
- Where
- United Kingdom
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- AbbVie
Antipsychotics, Cognition
Change in Brain Metabolism and Cognitive Function by Aripiprazole
Dopamine receptor occupancy and brain metabolism were measured using positron emission tomography after the administration of aripiprazole. Working memory performance was also measured using N-back task.
- Conditions
- Antipsychotics, Cognition, Brain Metabolism, Dopamine Receptor Occupancy
- Trial name
- NCT01562808
- Testing
- Aripiprazole
- Where
- South Korea
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Smoking Cessation, Tobacco Use Cessation
Exploring Occupancy of Dopamine D3 Receptor by Buspirone in Humans Using PET
The objective of the present study is to use positron emission tomography brain imaging to investigate D3 occupancy of buspirone, an FDA-approved anxiolytic which acts as a serotonin partial agonist but has recently been…
- Trial name
- NCT01699828
- Testing
- Buspirone
- Where
- Canada
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Centre for Addiction and Mental Health